Page Title
Clinical Trial Finder
Ask About Participating in This Study
Anti-InfectiveCompleted with Results
Study to evaluate inhaled molgramostim in adults 18 years and older with cystic fibrosis and an NTM infection in the lungs, protocol number Savara SAV008-02The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Anti-InfectiveCompleted with Results
Study to evaluate inhaled molgramostim in adults 18 years and older with cystic fibrosis and an NTM infection in the lungs, protocol number Savara SAV008-02
This study evaluated the effectiveness of inhaled molgramostim (Molgradex), a drug intended to treat nontuberculous mycobacterial (NTM) infections in the lungs of people with CF.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
30% or greater
-
Number of Visits:
19
-
Length of Participation:
72 weeks
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More